



Medical Education

Weaving the *red thread* towards cure in newly diagnosed multiple myeloma (NDMM)



Thursday 11th June 2026, 10:00–11:30 CEST
EHA2026 Congress

Nobel Hall, Stockholmsmässan, Mässvägen 1, 125 80 Älvsjö,
Stockholm, Sweden

Join us at the first of two multiple myeloma satellite symposia, supported by Johnson & Johnson at EHA 2026 and hosted by the Scientific Committee.

In this first symposium, we trace the red thread towards cure in NDMM, weaving together a decade of clinical milestones that have shaped the ever-evolving treatment landscape. We have lively debates on the different treatment strategies that could be adopted across two patients cases, and look at how self-administration can transform multiple myeloma care.

We look forward to welcoming you at the event!

This symposium is organised and sponsored by Johnson & Johnson and is not part of the official EHA scientific programme.

10:00–10:05

Welcome and introduction

Prof. María-Victoria Mateos (Chair)

10:05–10:25

Threading together 10 years of innovation in MM

Prof. María-Victoria Mateos (Chair) and Prof. Philippe Moreau

10:25–11:10

Debate: choose your red thread – applying evidence into everyday practice

Debate 1 – The need for transplant in the era of quads in transplant-eligible (TE) NDMM

Prof. María-Victoria Mateos (Chair) and Prof. Paula Rodríguez-Otero to debate; all faculty to participate in the discussion

Debate 2 – Quad vs Triplet in transplant-ineligible (TIE) NDMM: To V or not to V? That is the question

Prof. Philippe Moreau and Dr Charlotte Pawlyn to debate; all faculty to participate in the discussion

11:10–11:25

The red thread of possibility: how can self-administration transform multiple myeloma care?

Dr Charlotte Pawlyn to present and moderate; all faculty to participate in the discussion

11:25–11:30

3 red threads to take home

Prof. María-Victoria Mateos (Chair)

Symposium Committee:



Prof. María-Victoria Mateos (Chair)



Prof. Philippe Moreau

Faculty:



Prof. Paula Rodríguez-Otero



Dr Charlotte Pawlyn

The symposium will be broadcast live on the EHA congress website. An on-demand recording will be available for a limited time period, until October 15 2026, reflecting the content as presented live.



Organised and supported by Janssen Pharmaceutica NV,
a Johnson & Johnson company
Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse Belgium
Copyright © 2026 Janssen Pharmaceutica NV

Johnson&Johnson

EM-204364, 6/2026
EM-199284, 5/2026

Medical Education

Following the *red thread* in multiple myeloma (MM): aligning innovation with clinical practice



Friday 12th June 2026, 10:00–11:30 CEST
31st European Hematology Association Congress 2026

Nobel Hall, Stockholmsmässan, Mässvägen 1, 125 80 Älvsjö,
Stockholm, Sweden

Join us at the second of two multiple myeloma satellite symposia, supported by Johnson & Johnson at EHA 2026 and hosted by the Scientific Committee.

In this second symposium, we follow the red thread through to relapsed/refractory multiple myeloma (RRMM), weaving a story of innovation in first relapse and beyond. We will explore the evidence supporting CAR-T in $\geq 2L$ RRMM and its impact on long-term outcomes, clinical trial data and real-world evidence for bispecific antibodies in TCE RRMM, and how to optimise the usage of T cell-redirecting therapies in clinical practice. **We look forward to welcoming you at the event!**

This symposium is organised and sponsored by Johnson & Johnson and is not part of the official EHA scientific programme.

10:00–10:05

Welcome and introduction

Prof. María-Victoria Mateos (Chair)

Strengthening the red thread: clinical impact and emerging horizons for CAR-T in MM

10:05–10:20

Maximising long-term outcomes with CAR-T

Prof. María-Victoria Mateos (Chair), followed by panel discussion

10:20–10:35

Optimising early CAR-T use from evidence to practice

Prof. Elena Zamagni, followed by panel discussion

Extending the red thread: translating evidence for bispecific antibodies into clinical practice

10:35–10:50

BCMA-targeting bispecific antibodies in RRMM

Dr Roberto Mina, followed by panel discussion

10:50–11:10

Evolving clinical applications of GPRC5D-targeting bispecific antibodies

Dr Rakesh Popat, followed by panel discussion

11:10–11:30

Connecting the threads: practical insights across T cell-redirecting therapies in RRMM

Panel discussion, facilitated by Prof María-Victoria Mateos (Chair)

Scientific Committee:



Prof. María-Victoria Mateos (Chair)



Dr Rakesh Popat

Faculty:



Prof. Elena Zamagni



Dr Roberto Mina

The symposium will be broadcast live on the EHA congress website. An on-demand recording will be available for a limited time period, until October 15 2026, reflecting the content as presented live.

Organised and supported by Janssen Pharmaceutica NV,
a Johnson & Johnson company
Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse Belgium
Copyright © 2026 Janssen Pharmaceutica NV

Johnson & Johnson

EM-204364, 6/2026
EM-199285, 5/2026